

8th April 2013

To,

(a) BSE Limited
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

(b) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, Bandra Kurla Complex
Bandra (E)
Mumbai-400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(c) Societe De La Bourse De Luxembourg
Societe Anonyme
11, av de la Porte-Neuve
L-2227 Luxembourg


Dear Sirs,

Please find enclosed copy of Press Release dated 8th April 2013.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited



Mital Sanghvi
Company Secretary

Encl: as above



Cipla announces Result of Postal Ballot

Mumbai, India, 8th April 2013: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced the result of Postal Ballot. Pursuant to section 192A of the Companies Act, 1956 and the Companies (passing of the resolution by postal ballot) Rules, 2011, the Company had sought approval of members through Postal Ballot/E-voting on Special Resolution for issuance of stock options to Mr. Subhanu Saxena, Chief Executive Officer, as set out in the Notice dated 6th February 2013.

Upon submission of the report by the Scrutinizer, the Chairman announced at the Registered Office of the Company today that the Special Resolution for issuance of stock options to Mr. Subhanu Saxena, Chief Executive Officer has been passed with requisite majority.

About Cipla

Cipla laid the foundation for the Indian pharmaceutical industry in 1935, with the vision to make India self-reliant in healthcare. Over the years, Cipla has emerged as one of the most respected names not just in India but worldwide. Its state-of-the-art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. The company has over 34 manufacturing facilities across India, and manufactures 2,000+ products in 65 therapeutic categories.

With a turnover of over US \$ 1.4 billion, Cipla serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices.

Visit www.cipla.com

Media Contact:

Finance

Ajay Luharuka

Contact No.: +91-22-23025435

E-Mail: ajay@cipla.com

Corporate Communications

Jaisingh Balakrishnan

Contact No: +91-22-23025813

E-Mail: jaisingh.krishnan@cipla.com